InCrowd conducted 30-minute MicroQual interviews with four physicians considered key opinion leaders on Non-alcoholic Steatohepatitis (NASH). Then used this feedback to develop a 5-minute quantitative MicroSurvey for 55 gastroentologists and hepatologists.
Determine physician interests in and perspectives on NASH treatments in development.
Gauge the prevalence of comorbid conditions that require physician management alongside NASH and understand which physician specialties are ultimately stakeholders in patient care.
Method: 5-minute MicroSurvey via InCrowd
Crowds: US Gastroenterologists, Hepatologists
Sample Size: n=55
Fielding Period: April 25-26, 2018
One key insight: physicians feel that any effective treatment for NASH will need to be a combination regimen, versus a single agent, that helps resolve liver fibrosis, reduce liver inflammation, and interrupt the storage of fat in the liver.
Download the full report now!